A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence.

Trial Profile

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Alcohol withdrawal
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SENSE
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 09 Jun 2016 Results of a predictive microsimulation model assessing public health benefits of nalmefene and psychosocial support for the reduction of alcohol consumption from ESENSE1, ESENSE2 and SENSE trials published in the Applied Health Economics and Health Policy
    • 21 Oct 2014 Results for a subgroup of patients with comorbid mood disorders presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
    • 09 Oct 2013 Results for subgroup of patients with a high drinking risk level presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top